As the number of COVID-19 patients is dramatically increasing worldwide and treatment in intensive care units (ICU) has become a major challenge, early recognition of severe forms of COVID-19 is absolutely essential for timely triaging of patients. SARS-CoV-2 infection, especially in older patients and those with pre-existing illness, can progress to severe disease with critical respiratory symptoms and significant pulmonary changes visible by imaging techniques. The changes include ground glass opacities, patchy consolidation, alveolar exudates and interlobular involvement, ultimately prognosticating deterioration ([@bib0005]). Further to the recognised risk factors such as old age and underlying comorbidities--particularly cardiovascular diseases, diabetes, respiratory diseases, and other conditions ([@bib0010])--several markers have been identified that modulate the course of COVID-19. This paper summarises the laboratory markers that might be useful in indicating progression from mild to severe disease ([Table 1](#tbl0005){ref-type="table"} ).Table 1Haematological, cytokine, liver enzyme and coagulation parameters in mild versus severe COVID19 patients.Table 1**Haematological parametersCOVID-19 cases (n)InterpretationReference**White blood cell count (WBC)15 mild, 9 severe, 5 critical casesnormal or ↓ in 23/29([@bib0055])41 cases (13 ICU cases)↑ in ICU cases([@bib0005])43 (28 mild, 15 severe)normal in all cases([@bib0065])1,994 cases (meta-analysis)↓ in 29% of cases([@bib0075])54 casesnormal in cases([@bib0080])Neutrophil count41 cases (13 ICU cases)↑ in ICU cases([@bib0005])201 cases↑ in ARDS cases([@bib0085])12 cases↓ in most cases([@bib0090])Lymphocyte countFamilial cluster, 6 cases↓in 2 of 3 cases \> 60 years([@bib0095])15 mild, 9 severe, 5 critical cases↓ in 20/29([@bib0055])41 cases (13 ICU cases)↓ in ICU cases([@bib0005])140 cases↓ in most cases([@bib0100])43 (28 mild, 15 severe)normal in cases([@bib0065])1,994 cases (meta-analysis)↓ in most cases([@bib0075])54 cases↓ in most cases([@bib0080])12 cases↓ in most cases([@bib0090])30 cases↓ in 40% cases([@bib0105])70 mild, 85 severe cases↓ in all cases([@bib0070])Eosinophil count140 cases↓ in most cases([@bib0100])Thrombocyte countFamilial cluster, 6 cases↓ in 2 of 3 cases \> 60 years([@bib0095])70 mild, 85 severe casesnormal; slightly lower in severe cases([@bib0070])Granulocyte-colony stimulating factor (G-CSF)41 cases (13 ICU cases)↑ in ICU cases([@bib0005])CD8 cell count12 cases↓ in most cases([@bib0090])**CytokinesCOVID-19 cases (n)InterpretationReference**Tumour necrosis factor alpha (TNF-alpha)41 cases (13 ICU cases)↑ in ICU cases([@bib0005])Interferon-γ induced protein 10 (IP-10)41 cases (13 ICU cases)↑ in ICU cases([@bib0005])Monocyte chemoattractant protein 1 (MCP-1)41 cases (13 ICU cases)↑ in ICU cases([@bib0005])Chemokine (C-C Motif) Ligand 3 (CCL-3)41 cases (13 ICU cases)↑ in ICU cases([@bib0005])Interleukin-1 (IL-1)15 mild, 9 severe, 5 critical casesnormal in all cases([@bib0055])Interleukin-2 (IL-2)41 cases (13 ICU cases)↑ in ICU cases([@bib0005])Interleukin-2 receptor (IL-2R)15 mild, 9 severe, 5 critical cases↑, \> critical \> severe \> mild([@bib0055])Interleukin-6 (IL-6)15 mild, 9 severe, 5 critical cases↑ according to severity \> critical \> severe \> mild([@bib0055])69 cases, mortality 7.5%↑ in the patient group with SpO~2~ \< 90%([@bib0060])150 cases↑ in non-survivors([@bib0035])43: 28 mild, 15 severe cases↑ in severe cases([@bib0065])70 mild, 85 severe cases↑; higher in severe cases([@bib0070])Interleukin-7 (IL-7)41 cases (13 ICU cases)↑ in ICU cases([@bib0005])Interleukin-8 (IL-8)15 mild, 9 severe, 5 critical casesnormal in all cases([@bib0055])Interleukin-10 (IL-10)15 mild, 9 severe, 5 critical casesnormal in all cases([@bib0055])69 cases, mortality 7.5%↑ in the patient group with SpO~2~ \< 90%([@bib0060])41 cases (13 ICU cases)↑ in ICU cases([@bib0005])**Liver enzymes/biomarkersCOVID-19 cases (n)InterpretationReference**Albumin15 mild, 9 severe, 5 critical cases↓in 15/29([@bib0055])41 cases (13 ICU cases)↓ in ICU cases([@bib0005])12 cases↓ in most cases([@bib0090])70 mild, 85 severe cases↓ in all cases([@bib0070])Alanine aminotransferase (ALT)15 mild, 9 severe, 5 critical cases-([@bib0055])41 cases (13 ICU cases)↑ in ICU cases([@bib0005])Aspartate aminotransferase (AST)15 mild, 9 severe, 5 critical cases-([@bib0055])Total bilirubin41 cases (13 ICU cases)↑ in ICU cases([@bib0005])15 mild, 9 severe, 5 critical cases- normal in all cases([@bib0055])Glucose43: 28 mild, 15 severe cases↑ in severe cases([@bib0065])Serum creatinine126 mild, 24 severe cases↑ in severe cases([@bib0055])Lactate dehydrogenase (LDH)Familial cluster, 6 cases↑ in the 3 cases \>60 yrs.([@bib0095])15 mild, 9 severe, 5 critical cases↑ in 20/29([@bib0055])69 cases, mortality 7,5%↑ in the patient group with SpO~2~ \< 90%([@bib0060])41 cases (13 ICU cases)↑ in ICU cases([@bib0005])201 cases↑ in ARDS cases([@bib0085])1,994 cases (meta-analysis)↑ in 28% of cases([@bib0075])54 cases↑ in most cases([@bib0080])12 cases↑ in all cases([@bib0090])70 mild, 85 severe cases↑ in severe cases([@bib0070])C-reactive protein (CRP)Familial cluster, 6 cases↑ in the 3 cases \>60 yrs.([@bib0095])126 mild, 24 severe caseshigher in severe cases([@bib0110])15 mild, 9 severe, 5 critical cases↑ in 27/29([@bib0055])69 cases, mortality 7,5%↑ in cases with SpO~2~ \< 90%([@bib0060])140 cases↑ in severe cases([@bib0100])43: 28 mild, 15 severe cases↑ in severe cases([@bib0065])1,994 cases (meta-analysis)↑ in 44% of cases([@bib0075])54 cases↑ in most cases([@bib0080])12 cases↑ in most cases([@bib0090])70 mild, 85 severe cases↑ in all cases, higher in severe cases([@bib0070])Procalcitonin (PCT)140 cases↑ in severe cases([@bib0100])70 mild, 85 severe cases↑ in all cases([@bib0070])Ferritin150↑ in non-survivors([@bib0035])NT-proBNP126 mild, 24 severe cases↑ in severe cases([@bib0110])Cardiac troponin I126 mild, 24 severe cases↑ in severe cases([@bib0110])Cardiac troponin I (meta-analysis)218 mild, 123 severe cases↑ in severe cases([@bib0045])138 hospitalised severe cases↑ in severe cases([@bib0050])Angiotensin II level12 cases↑ in cases([@bib0090])**Coagulation parametersCOVID-19 cases(n)InterpretationReference**d-dimers191 cases, 91 with comorbidities↑ in non-survivors([@bib0010])94 cases↑ in cases vs. controls([@bib0115])201 cases↑ in ARDS cases([@bib0085])140 cases↑ in severe cases([@bib0100])43: 28 mild, 15 severe cases↑ in severe cases([@bib0065])30 cases↑ in 17% of cases([@bib0105])70 mild, 85 severe casesnormal; slightly higher in severe cases([@bib0070])183 cases; 21 non-survivors↑ in all cases, higher in non-survivors([@bib0040])Antithrombin (AT)94 cases↓ in cases vs. controls([@bib0115])Prothrombin time (PT)94 cases↓ in cases vs. controls([@bib0115])41 cases (13 ICU cases)↑ in ICU cases([@bib0005])183 cases; 21 non-survivors↑ in non-survivors([@bib0040])Activated partial thromboplastin time (APTT)183 cases; 21 non-survivors↑ in non-survivors([@bib0040])Thrombin clotting time (TCT)94 casesshorter in critical cases vs. controls([@bib0115])43: 28 mild, 15 severe cases↑ in severe cases([@bib0065])Fibrin degradation products (FDP)94 cases↑ in cases vs. controls([@bib0115])183 cases; 21 non-survivors↑ in non-survivors([@bib0040])Fibrinogen94 cases↑ in cases vs. controls([@bib0115])43: 28 mild, 15 severe cases↑ in severe cases([@bib0065])183 cases; 21 non-survivors↑ in all cases, higher in non-survivors([@bib0040])[^2]

COVID-19 patients admitted to ICUs have been found to have higher concentrations of proinflammatory cytokines and, importantly, increased secretion of those T-helper-2 (Th2) cytokines suppressing inflammation ([@bib0005]). Given the high levels of cytokines induced by SARS-CoV-2, treatment to reduce inflammation-related lung damage is critical. However, any intervention to reduce inflammation will negatively affect viral clearance. Among the various inflammatory cytokine and chemokine levels assessed in several studies, tumour necrosis factor alpha (TNF-α), interferon-γ-induced protein 10 (IP-10), monocyte chemoattractant protein 1 (MCP-1), chemokine (C-C motif), ligand 3 (CCL-3), and distinct interleukins (IL) (IL-2, IL-6, IL-7, IL-10) were significantly associated with disease severity and particularly observed among cases admitted to ICUs. IL-1 and IL-8 were not associated with severity ([Table 1](#tbl0005){ref-type="table"}). Apparently, the serum levels of some interleukins have the potential to discriminate between mild and severe disease and possibly may be used as prognostic markers.

Among haematological parameters, lymphopenia is clearly associated with disease severity; patients who have died from COVID-19 have had significantly lower lymphocyte counts than survivors. In fact, repletion of lymphocytes may be an important factor for recovery ([@bib0015]). Other blood cells--including white blood cells, neutrophils, eosinophils, platelets, and CD8 cell counts--were partial predictors in discriminating mild from severe COVID-19 ([Table 1](#tbl0005){ref-type="table"}); their significance is still ambiguous. Granulocyte colony stimulating factor (G-CSF) has been found to be elevated in ICU patients and significantly associated with disease severity ([Table 1](#tbl0005){ref-type="table"}).

Patients with severe COVID-19 appear to have more frequent signs of liver dysfunction than those with milder disease. An increase in alanine aminotransferase (ALT), aspartate aminotransferase (AST) and total bilirubin levels has been observed among many ICU patients ([@bib0020]) ([Table 1](#tbl0005){ref-type="table"}). Infection of liver cells with SARS-CoV-2 cannot be excluded as 2--10% of patients with COVID-19 have diarrhoea and viral RNA has been detected in both stool and blood samples, which implies the possibility of hepatic virus presence ([@bib0025]). It is also likely that any immune-mediated inflammation, in particular cytokine storm, but also pneumonia-associated hypoxia, may lead to liver damage in critically ill COVID-19 patients ([@bib0020]). C-reactive protein (CRP) levels are increased in COVID-19 patients and it has been shown that survivors had median CRP values of approximately 40 mg/L, while non-survivors had median values of 125 mg/L, indicating a strong correlation with disease severity and prognosis ([@bib0030]) ([Table 1](#tbl0005){ref-type="table"}). Other predictors of poor outcome include the serum levels of ferritin and lactate dehydrogenase (LDH). Elevated ferritin levels due to secondary haemophagocytic lymphohistiocytosis (sHLH) and cytokine storm syndrome have been reported in severe COVID-19 patients. Based on body temperature, organomegaly, blood cell cytopenia, triglycerides, fibrinogen, AST and ferritin levels, a predictive H-score has been proposed to estimate the risk of developing secondary haemophagocytic lymphohistiocytosis ([@bib0035]).

Correlations of abnormal coagulation parameters with poor prognosis have been observed ([Table 1](#tbl0005){ref-type="table"}). Non-survivors have shown significantly higher levels of plasma D-dimers and fibrin degradation products, increased prothrombin times and activated partial thromboplastin times compared to survivors ([@bib0040]). Coagulopathy and overt disseminated intravascular coagulation appear to be associated with high mortality rates. Among the coagulation parameters, D-dimer elevation \> 1 ug/L was the strongest independent predictor of mortality ([@bib0010]). Elevated cardiac troponin I levels indicating heart injury were also predictive of mortality in critically ill patients ([@bib0045], [@bib0050]).

The haematological and coagulation parameters summarised here and increased inflammatory reactions caused by various cytokines and liver enzymes are a globally observed phenomenon in COVID-19 patients. While the clinical status (in particular SpO~2~ levels) and concurrent comorbidities of COVID-19 patients largely determine the need for their admittance to ICUs, several laboratory parameters may facilitate the assessment of disease severity and rational triaging. It is more likely that the course of the disease will be unfavourable if some or all of these parameters are altered. Clinicians should consider low lymphocyte count and the serum levels of CRP, D-dimers, ferritin, cardiac troponin and IL-6, which may be used in risk stratification to predict severe and fatal COVID-19 in hospitalised patients. In order to further support clinical decision-making, large datasets and sound meta-analyses are now urgently required.
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